[Anticoagulant therapy in cardiology: yesterday, today, tomorrow].
Panchenko
E P
EP
D000925:Anticoagulants / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects; D025901:Carboxypeptidase B2 / Q000502:physiology; D002318:Cardiovascular Diseases / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D017326:Clinical Trials, Phase III as Topic; D000069604:Dabigatran; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects; D044463:Receptor, PAR-1 / Q000502:physiology; D000069552:Rivaroxaban; D013876:Thiophenes / Q000627:therapeutic use; D013917:Thrombin / Q000502:physiology; D018180:Thrombomodulin / Q000502:physiology; D013927:Thrombosis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects
D000925:Anticoagulants; D001562:Benzimidazoles; D005343:Fibrinolytic Agents; D009025:Morpholines; D011725:Pyridines; D044463:Receptor, PAR-1; D013876:Thiophenes; D018180:Thrombomodulin; D014859:Warfarin; D000069552:Rivaroxaban; D025901:Carboxypeptidase B2; D013917:Thrombin; D000069604:Dabigatran